Telik Inc. raised S26 million through its follow-on public offering of 4 million shares at $6.50 per share, under the $37.3 million estimated net proceeds, but plenty to boost its work with TLK286 and TLK199, as well as its class of orally active insulin receptor activators. "We can proceed as planned, with the same priorities, with these funds," said Michael Wick, president and CEO of South San Francisco-based Telik, adding that he was bound by regulatory quiet-period rules from saying much more. Telik registered for the …
No comments:
Post a Comment